Crypto Industry Lobbies Trump and His Allies After Election Wins
Posted inArmstrong, Brian (1983- ) Bitcoin (Currency) Cantor Fitzgerald LP Coinbase Inc Computers and the Internet Corporations Gensler, Gary S Law and Legislation Lobbying and Lobbyists Lutnick, Howard W Presidential Election of 2024 Regulation and Deregulation of Industry Ripple Labs Inc Securities and Exchange Commission Trump, Donald J United States Politics and Government Virtual Currency

Crypto Industry Lobbies Trump and His Allies After Election Wins

As Bitcoin soars to record highs, cryptocurrency executives are maneuvering to influence Donald J. Trump’s transition and secure their policy goals.
The Crypto Industry’s Spending on the Election Pays Off
Posted inAndreessen Horowitz Campaign Finance Coinbase Inc Elections, House of Representatives Elections, Senate FairShake Inc HK FTX Trading Ltd (Futures Exchange) Law and Legislation Midterm Elections (2022) Moreno, Bernie (1967- ) Political Action Committees Politics and Government Porter, Katie (1974- ) Presidential Election of 2024 Regulation and Deregulation of Industry Securities and Exchange Commission Tester, Jon United States Politics and Government Virtual Currency

The Crypto Industry’s Spending on the Election Pays Off

The spending spree fueled a string of victories on Tuesday for congressional candidates who had expressed support for cryptocurrencies.
Victims of Stanford Financial’s Fraud Scheme May Soon Be Paid. Some Already Sold Their Claim.
Posted inBaker Botts LLP Banking and Financial Institutions Certificates of Deposit Compensation for Damages (Law) Customer Relations Madoff, Bernard L Ponzi and Pyramid Schemes Securities and Exchange Commission Stanford, Robert Allen Stocks and Bonds

Victims of Stanford Financial’s Fraud Scheme May Soon Be Paid. Some Already Sold Their Claim.

Not having much insight into what may happen next in the case of a fraud orchestrated by Robert Allen Stanford, many of the victims sold the rights to any future payout.
Officials Cast Doubt on a Dementia Drug, but Human Trials Continue
Posted inAcademic and Scientific Journals Alzheimer's Disease Cassava Sciences Inc City University of New York Clinical Trials Dementia Drugs (Pharmaceuticals) Falsification of Data Food and Drug Administration Regulation and Deregulation of Industry Securities and Commodities Violations Securities and Exchange Commission United States Wang, Hoau-Yan your-feed-science

Officials Cast Doubt on a Dementia Drug, but Human Trials Continue

The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement. Some experts wonder why clinical trials have not been stopped.